LEVEMIR

ApprovedSmall molecule

Novo Nordisk

LEVEMIR is one of 37 small molecule programs targeting Type 2 Diabetes. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

EmergenciesWithdrawn

Type 2 DiabetesApproved

Active, not recruiting

EmergenciesPreclinical

Withdrawn

Competition

Competitive Landscape

165 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

LEVEMIR

Novo Nordisk

Approved

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

GLP-1

RRigshospitalet, Denmark

Preclinical

2 9

Routine Treatment

GSK

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes

Terminated·—·Phase 4·NCT02048189·14 enrolled

Emergencies1 trial

Sub-Cutaneous Insulin in Hyperglycaemic Emergencies

Withdrawn·—·N/A·NCT00467246

MPA1 trial

Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections

Completed·RRabin Medical Center·Phase 4·NCT00542399·50 enrolled

Double-blind1 trial

A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial

Completed·MMedical University of Graz·Phase 1·NCT00810589·30 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 16, 2005

LEVEMIR

BLA BLA021536

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for LEVEMIR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LEVEMIR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LEVEMIR. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA021536). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novo Nordisk

LEVEMIR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes1 trial

Emergencies1 trial

MPA1 trial

Double-blind1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News